Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FPR3 | P25089 | 4/20 | 0.47 |
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085154 | 0.86 | MGLL (0.48) | TDP1CA1CA2KMT2AMEN1 | |
| SCHEMBL24350075 | 0.86 | NPC1 (0.54) | TDP1CA1CA2KMT2AMEN1 | |
| SCHEMBL1929771 | 0.86 | SIGMAR1 (0.52) | HDAC1HDAC8TDP1CA1CA2 | |
| SCHEMBL20649129 | 0.84 | NPC1 (0.58) | TDP1FPR3FPR2ALDH1A1KMT2A | |
| SCHEMBL13114818 | 0.84 | CA1 (0.46) | TDP1CA1CA2ALDH1A1KMT2A | |
| SCHEMBL23992278 | 0.83 | STK17B (0.46) | TDP1FPR3FPR2CA1CA2 | |
| SCHEMBL204168 | 0.82 | ALDH1A1 (0.50) | HDAC1HDAC8FPR3FPR2ALDH1A1 | |
| SCHEMBL24746443 | 0.82 | CA1 (0.45) | TDP1CA1CA2KMT2AMEN1 | |
| SCHEMBL205459 | 0.82 | CA1 (0.45) | TDP1CA1CA2KMT2AMEN1 | |
| SCHEMBL29925130 | 0.82 | CA1 (0.45) | TDP1CA1CA2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331739-A1 | INDOLO HEPTAMYL OXIME ANALOG CRYSTAL AS PARP INHIBITOR AND METHOD FOR PREPARING SAME | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331739-A1 | INDOLO HEPTAMYL OXIME ANALOG CRYSTAL AS PARP INHIBITOR AND METHOD FOR PREPARING SAME | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3919495-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020156577-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-2635560-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012059371-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| WO-2011130661-A1 | METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | HDAC1 67/4885HDAC8 263/4885TDP1 93/4885 |
| US-20230331739-A1 | INDOLO HEPTAMYL OXIME ANALOG CRYSTAL AS PARP INHIBITOR AND METHOD FOR PREPARING SAME | PARP1, PARP2, PARP8 | HDAC1 527/4885HDAC8 1119/4885TDP1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.